KING OF PRUSSIA, Pa., Feb. 11, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted Privigen® (Immune Globulin ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is thought to be an autoimmune condition. When you have CIDP, your immune system sees your nerves as foreign and attacks them. The attack ...

Privigen (human immunoglobulin G) is a prescription drug used to treat certain immune system conditions. The drug comes as an intravenous (IV) infusion (an injection into a vein given over time).

The prescribed dosage for Privigen (human immunoglobulin g) may vary depending on a person’s individual treatment plan. Other factors, including your specific diagnosis, body weight, and medical ...

This pilot open label study investigated the safety and preliminary efficacy of using IVIG over a 6-month period for treatment of MSA. IVIG treatment was well tolerated. Post-treatment functional ...

Data published online in the current edition of Journal of Clinical Immunology demonstrates that Privigen TM, the new liquid immune globulin intravenous (human) 10 percent product from CSL Behring, is ...

The FDA approval was based on data from two Phase 3 studies, PATH and PRIMA. CSL Behring announced that the Food and Drug Administration (FDA) has approved Privigen (immune globulin intravenous [human ...

The price you pay for Privigen may depend on factors such as your dosage, whether you have health insurance. Financial assistance may be available to help you with the cost of Privigen. your treatment ...

KING OF PRUSSIA, Pa., July 20, 2018 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that it will support the presentation of 14 scientific posters at the 2018 annual meeting ...

This was a single-arm, interventional-, single-center, open-label prospective study. Patients with a history of probable MSA [15] were enrolled in the study (Table 1). All patients had some ...